Author

Jerry Tan Chun Bing

Observed name: J.T.C. Bing

Institution: Cebu Doctors' University

Observed institution: Cebu Doctors' University

ORCID: 0009-0000-2728-5331

Observed ORCID: 0009-0000-2728-5331

OpenAlex ID: A5055013502

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

2019 · Tony S K Mok, Yi-Long Wu, et al. · The Lancet · 3,479

Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non–Small Cell Lung Cancer: The Phase III PACIFIC-2 Study

2025 · Jeffrey D. Bradley, Shunichi Sugawara, et al. · Journal of Clinical Oncology · 97

Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE‐158 study

2023 · Do‐Youn Oh, Alain Algazi, et al. · Cancer · 67

Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial

2026 · R. Dent, Z. Shao, et al. · Annals of Oncology · 52

Patient-Reported Outcomes in FLAURA2: Osimertinib with or without Chemotherapy in Patients with Previously Untreated EGFR-Mutated Advanced Non–Small Cell Lung Cancer

2026 · Jhanelle E. Gray, Konstantin Laktionov, et al. · Clinical Cancer Research · 2

Data from Patient-Reported Outcomes in FLAURA2: Osimertinib with or without Chemotherapy in Patients with Previously Untreated EGFR-Mutated Advanced Non–Small Cell Lung Cancer

2026 · Jhanelle E. Gray, Konstantin Laktionov, et al.

Supplementary Data from Patient-Reported Outcomes in FLAURA2: Osimertinib with or without Chemotherapy in Patients with Previously Untreated EGFR-Mutated Advanced Non–Small Cell Lung Cancer

2026 · Jhanelle E. Gray, Konstantin Laktionov, et al.

P3.12.65 First-Line Osimertinib ± Platinum-Pemetrexed in EGFR-Mutated Advanced NSCLC: FLAURA2 Clinical Outcomes by EGFRm Subtype

2025 · S. Ahmed, J.C.-H. Yang, et al. · Journal of Thoracic Oncology

Works count: 8

Citation count: 3,697

H-index: 4

I10-index: 4